Stealth BioTherapeutics, a Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction, raised $78 million by offering 6.5 million shares at $12, the low end of the range of $12 to $14. Stealth BioTherapeutics plans to list on the Nasdaq under the symbol MITO. Jefferies, Evercore ISI and BMO Capital Markets acted as lead managers on the deal.
